Serum concentrations of cancer antigen 125 (CA 125) were determinedfor 373 patients with various liver diseases: 57 with acute hepatitis, 57 with chronic hepatitis, 244 with liver cirrhosis (86 compensated and 158 decompensated), and 15 with primary liver cancer. The antigen was measured simultaneously in the serum and ascitic fluid of 46 of the patients with liver cirrhosis and sequentially in the serum and ascitic fluid of another 25 cirrhotics treated with paracentesis and (or) diuretics. Abnormal results for CA 125 were detected in sera from 4% of the patients with acute or chronic hepatitis, 60% of the patients with liver cirrhosis, and 67% of the patients with primary liver cancer. The main factor associated with abnormal serum concentrations of this antigen was the presence of ascites, with pathological CA 125 values in 94% of patients with ascites without jaundice (mean 566 ± 528 arb. units/mL), compared with only 40% of patients with jaundice and without ascites (mean 40.1 ± 28.5 arb. unitsfmL) (P <0.001). High concentrations of CA 125 were mainly associated with spontaneous bacterial peritonitis. The serum concentration of CA 125 decreased after treatment with paracentesis, but increased in patients treated with diuretics rather than paracentesis. The release of this antigen in liver cirrhosis appears to be independent of the liver disorder and, rather, results from peritoneal synthesis of this antigen. 
found in these two groups of patients; however, the concentrations were significantly higher in the cirrhotic and cancer patients than in the patients with acute or chronic hepatitis without cirrhosis (P <0.0001).
The patients with decompensated cirrhosis presented higher CA 125 concentrations than did compensated patients with cirrhosis (Table 1 ) (P <0.0001). The latter group had CA 125 serum concentrations similar tothose found in the patients with acute or chronic hepatitis.
The possible relationship between CA 125 serum concentrations and the etiology of the liver cirrhosis is explored in Table 2 . We saw no obvious relationship between the physiopathology of liver cirrhosis and the serum concentrations of this tumor marker. The highest values for CA 125 were found in decompensated cirrhotics, independent of etiology. Table 4 shows the CA 125 serum concentrations in patients with decompensated cirrhosis in relation to the presence of ascites and the concentration of bilirubin. The majority of patients with ascites (86 of 96) again presented with above-normal CA 125 concentrations, independent of the bilirubin concentrations.
Of the patients with jaundice (bilirubin >60 pmol/L) but without ascites, 40% also had above-normal CA 125 concentrations, although lower than those found in patients with ascites (P <0.0001). Figure 1 shows the CA 125 concentrations found in ascitic fluid and in serum from the patients with decom- 5 arb. units/mL). In the cases with ascites, the concentration was higher in blood from the suprahepatic vein (407 ± 407 arb. units/mL) than inperipheral blood (364 ± 330 arb. units/mL), although the differences were not significant.
Discussion
Several studies have indicated the utility of CA 125 in follow-up of patients with ovarian carcinoma (4) (5) (6) (7) (8) . Like many other tumor markers, CA 125 is not a tissue-or tumor-specific antigen; thus, above-normal concentrations of it are found in serum in several benign and neoplastic pathologies (4, 5, (9) (10) (11) (12) (13) (14) (15) . The majority of false-positive results arise in association with liver diseases, particularly cirrhosis (12,13,16-18) .
Liver diseases without malignant transformation are frequently associated with increases of various tumor markers in serum, including alpha-fetoprotein, carcinoembryonic antigen, and cancer antigen 19.9 (CA 19.9) (21-24). The causes for the association of tumor markers with liver diseases vary. For example, increases in serum alpha-fetoprotein arise in association with liver regeneration (21,25), whereas disorders in catabolism and excretion are often associated with increases in carcinoembryonic antigen or CA 19.9 (22-24). Our observation of above-normal CA 125 in patients with liver diseases argues against cytolysis as the cause for the increase of CA 125 detected in liver diseases. The incidence of above-normal CA 125 in hepatitis, independent of etiology, was 4.4%, with mean values being the normal range. These results are similar to those described by our group in previous studies and by others (12, 13, 16-18 and increased concentrations of CA 125. In our experience, the serum concentrations of this marker are independent of the etiology of the cirrhosis, whereas in all types of cirrhosis, increased CA 125 is observed, mainly among patients with decompensated liver disease.
The presence of ascites and the bilirubin concentration are the variables most frequently used to assess the existence of liver decompensation (20) . Bilirubin does not seem to be related to increases in CA 125 concentrations. Furthermore, the CA 125 concentrations in patients with primary biliary cirrhosis, a highly cholestatic chronic liver disease, were similar to those seen in cirrhosis of other etiologies-results that contradict those reported by Eerdekens et al. (19) .
In contrast, the presence of ascites seems to play a key role in the mechanism responsible for increased CA 125. The mean concentration of CA 125 is much higher in cirrhotic patients with ascites than in patients without ascites and also is higher than in jaundiced patients (P <0.0001). These results are similar to those previously reported by our group Inconclusion, our results suggest that the main cause for the increase of serum CA 125 in various benignliver diseases is the presence of cirrhosis and ascites. This antigen may be synthesized in the pleural mesothelium and released into the ascitic fluid or serum. The ascitic fluid may act as a reservoir for the antigen, which then passes into the circulation.
